BioCentury | Sep 14, 2017
Strategy

Numerate’s Intelligence

...cases,” he added. At least 20 other companies are using machine learning tools to facilitate translational drug development...
BioCentury | Apr 16, 2015
Distillery Therapeutics

Therapeutics: An undetermined target

...Jeffrey P. MacKeigan, Van Andel Research Institute, Grand Rapids, Mich. e-mail: jeff.mackeigan@vai.org CONTACT: Stephen Gately, Translational Drug Development...
BioCentury | Sep 23, 2013
Clinical News

Minnelide: Phase I started

...The Translational Drug Development (TD2) subsidiary of the not-for-profit Translational Genomics Research Institute (Phoenix, Ariz.) began an open-label...
BioCentury | Feb 18, 2013
Company News

Albany Molecular Research, Bessor Pharma deal

Translational drug development company Bessor exercised a 2012 option from contract research and manufacturing services company AMRI to license exclusive, worldwide rights to IP related to cancer compound ALB 109564(a) . Bessor formed its affiliate Chai...
BioCentury | Apr 9, 2012
Company News

Albany Molecular Research, Bessor Pharma deal

...Contract research and manufacturing services company Albany Molecular granted translational drug development company Bessor an eight-month option to...
BioCentury | Sep 5, 2005
Strategy

Back to School 2005: Innovation & economics

...QB3 partners with PharmaStart, a consortium of research organizations led by SRI International that offers translational drug development...
Items per page:
1 - 6 of 6
BioCentury | Sep 14, 2017
Strategy

Numerate’s Intelligence

...cases,” he added. At least 20 other companies are using machine learning tools to facilitate translational drug development...
BioCentury | Apr 16, 2015
Distillery Therapeutics

Therapeutics: An undetermined target

...Jeffrey P. MacKeigan, Van Andel Research Institute, Grand Rapids, Mich. e-mail: jeff.mackeigan@vai.org CONTACT: Stephen Gately, Translational Drug Development...
BioCentury | Sep 23, 2013
Clinical News

Minnelide: Phase I started

...The Translational Drug Development (TD2) subsidiary of the not-for-profit Translational Genomics Research Institute (Phoenix, Ariz.) began an open-label...
BioCentury | Feb 18, 2013
Company News

Albany Molecular Research, Bessor Pharma deal

Translational drug development company Bessor exercised a 2012 option from contract research and manufacturing services company AMRI to license exclusive, worldwide rights to IP related to cancer compound ALB 109564(a) . Bessor formed its affiliate Chai...
BioCentury | Apr 9, 2012
Company News

Albany Molecular Research, Bessor Pharma deal

...Contract research and manufacturing services company Albany Molecular granted translational drug development company Bessor an eight-month option to...
BioCentury | Sep 5, 2005
Strategy

Back to School 2005: Innovation & economics

...QB3 partners with PharmaStart, a consortium of research organizations led by SRI International that offers translational drug development...
Items per page:
1 - 6 of 6